Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Apr 08 2026

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Dapagliflozin Tablets in two dosages. With this approval, Zydus gains eligibility for a period of shared generic drug exclusivity for the product.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases